علاج الصرع الغيابي لدى الأطفال مع نوبات الغياب فقط عندما لا يحقق الإيثوسكسيميد التحرر من النوبات

References

1. The treatment of choice for CAE with absence seizures only is ethosuximide.
2. Therefore, based on the CAE trial, ETX is the drug of choice as initial monotherapy for CAE, when absence seizures are the only seizure type, but there are specific treatment considerations for each drug, which are discussed below.
3. Persistent seizures or AE on ETX, or presence of GTC seizures: Treat with VPA
4. VPA is also preferred as a second treatment when ETX fails, whether due to efficacy or tolerability reasons, based on a crossover extension phase of the CAE study.
5. The target serum level is the level at which absence seizures stop occurring, both by parent report and by EEG — that is, there is no need to increase the dose to reach an arbitrarily set serum level.
6. However, for most patients, the therapeutic range is 50–100 µg/dL, and in the absence of side effects, serum levels can be pushed even higher to 120 µg/dL, or perhaps even 150 µg/dL.